Bristol-Myers Squibb Co.
NYSE:BMY 3:58:04 PM EDT
Other Pre-Announcement
Bristol Myers Squibb - Q4 GAAP EPS $0.95 Q4 Non-GAAP EPS $1.82
Published: 02/02/2023 12:25 GMT
Bristol-Myers Squibb Co. (BMY) - Bristol Myers Squibb - Q4 GAAP EPS $0.95; Q4 Non-GAAP EPS $1.82.
Bristol Myers Squibb - Q4 Eliquis Revenue $2.69 Billion Versus $2.67 Billion.
Bristol Myers Squibb - Q4 Opdivo Revenue $2.22 Billion Versus $1.99 Billion.
Bristol Myers Squibb - Sees 2023 GAAP EPS $4.03 - $4.33; Sees 2023 Non-GAAP EPS $7.95 - $8.25.
Bristol Myers Squibb - Q4 Revenues of $11.41 Billion Versus $11.99 Billion.
Bristol Myers Squibb - Sees 2023 Total Revenue to Increase by About 2% at Reported Rates and About 2% Excluding Fx.
Bristol Myers Squibb - Q4 Revlimid Revenue $2.26 Billion Versus $3.33 Billion.
Bristol Myers Squibb - 2023 Revenues From Revlimid Expected to Be About $6.5 Billion.
Further Company Coverage: Bmyn ((reuters.
Briefs@thomsonreuters.
Com;)).
Bristol Myers Squibb - Q4 Eliquis Revenue $2.69 Billion Versus $2.67 Billion.
Bristol Myers Squibb - Q4 Opdivo Revenue $2.22 Billion Versus $1.99 Billion.
Bristol Myers Squibb - Sees 2023 GAAP EPS $4.03 - $4.33; Sees 2023 Non-GAAP EPS $7.95 - $8.25.
Bristol Myers Squibb - Q4 Revenues of $11.41 Billion Versus $11.99 Billion.
Bristol Myers Squibb - Sees 2023 Total Revenue to Increase by About 2% at Reported Rates and About 2% Excluding Fx.
Bristol Myers Squibb - Q4 Revlimid Revenue $2.26 Billion Versus $3.33 Billion.
Bristol Myers Squibb - 2023 Revenues From Revlimid Expected to Be About $6.5 Billion.
Further Company Coverage: Bmyn ((reuters.
Briefs@thomsonreuters.
Com;)).